Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the...
-
SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...
-
Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors CLIO-8221 is the first program from...
-
Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren,...
-
Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates,...
-
Quarterly net revenues were RMB1,000.5 million (US$143.1 million)1Quarterly lidar shipments were 631,095 unitsQuarterly net income was RMB153.2 million (US$21.9 million)Full year 2025 net revenues...
-
– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned...
-
Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first...
-
ALBANY, New York, March 20, 2026 (GLOBE NEWSWIRE) -- Curia, sebuah organisasi penyelidikan, pembangunan dan pembuatan kontrak (CDMO) terkemuka, hari ini mengumumkan kemajuan dalam pengembangan...
-
미국 뉴욕주 올버니, March 20, 2026 (GLOBE NEWSWIRE) -- 글로벌 위탁연구·개발·생산(CDMO) 기업인 Curia가 영국 글래스고에 위치한 무균 의약품 생산 시설의 확장 진행 상황과 함께, 자사의 세포주 개발 플랫폼 고도화에 대한 성과를 오늘 발표했다. 영국 글래스고 사이트는 제형 개발, 동결건조(lyophilization)...